These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 8581422)
21. Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen. Moreau E; Hoebeke J; Zagury D; Muller S; Desgranges C J Virol; 2004 Apr; 78(7):3792-6. PubMed ID: 15016898 [TBL] [Abstract][Full Text] [Related]
22. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-on e (TIBO) derivatives. 2. Kukla MJ; Breslin HJ; Diamond CJ; Grous PP; Ho CY; Miranda M; Rodgers JD; Sherrill RG; De Clercq E; Pauwels R J Med Chem; 1991 Nov; 34(11):3187-97. PubMed ID: 1956037 [TBL] [Abstract][Full Text] [Related]
23. A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor. Montembault M; Vo-Thanh G; Deyine A; Fargeas V; Villiéras M; Adjou A; Dubreuil D; Esquieu D; Grégoire C; Opi S; Péloponèse JM; Campbell G; Watkins J; de Mareuil J; Aubertin AM; Bailly C; Loret E; Lebreton J Bioorg Med Chem Lett; 2004 Mar; 14(6):1543-6. PubMed ID: 15006399 [TBL] [Abstract][Full Text] [Related]
24. Doxorubicin inhibits Tat-dependent transactivation of HIV type 1 LTR. Jeyaseelan R; Kurabayashi M; Kedes L AIDS Res Hum Retroviruses; 1996 May; 12(7):569-76. PubMed ID: 8743082 [TBL] [Abstract][Full Text] [Related]
25. The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication. Accolla RS; Mazza S; De Lerma Barbaro A; De Maria A; Tosi G Eur J Immunol; 2002 Oct; 32(10):2783-91. PubMed ID: 12355430 [TBL] [Abstract][Full Text] [Related]
26. A Tat antagonist inhibits HIV-1 induction in naturally infected and experimentally infected T cells. Potash MJ; Bentsman G; McKinley G; Volsky DJ Biochem Biophys Res Commun; 1992 Nov; 189(1):250-6. PubMed ID: 1449479 [TBL] [Abstract][Full Text] [Related]
27. New AIDS drug poised to move into development. Science; 1991 Dec; 254(5039):1715. PubMed ID: 1763318 [No Abstract] [Full Text] [Related]
28. Keto/enol epoxy steroids: a new structural class of HIV-1 Tat inhibitors. Michne WF; Schroeder JD; Bailey TR; Young DC; Hughes JV; Dutko FJ J Med Chem; 1993 Sep; 36(18):2701-2. PubMed ID: 8410982 [No Abstract] [Full Text] [Related]
29. 1,2,5-Benzothiadiazepine and pyrrolo[2,1-d]-[1,2,5]benzothiadiazepine derivatives with specific anti-human immunodeficiency virus type 1 activity. Di Santo R; Costi R; Artico M; Massa S; Marongiu ME; Loi AG; De Montis A; La Colla P Antivir Chem Chemother; 1998 Mar; 9(2):127-37. PubMed ID: 9875384 [TBL] [Abstract][Full Text] [Related]
30. Potent and selective inhibition of Tat-dependent HIV-1 replication in chronically infected cells by a novel naphthalene derivative JTK-101. Wang X; Yamataka K; Okamoto M; Ikeda S; Baba M Antivir Chem Chemother; 2007; 18(4):201-11. PubMed ID: 17907378 [TBL] [Abstract][Full Text] [Related]
32. HIV-1 Tat protein and its inhibitor Ro 24-7429 inhibit lymphocyte proliferation and induce apoptosis in peripheral blood mononuclear cells from healthy donors. Patki AH; Lederman MM Cell Immunol; 1996 Apr; 169(1):40-6. PubMed ID: 8612292 [TBL] [Abstract][Full Text] [Related]
34. Inhibitors of HIV-1 Tat-mediated transactivation. Richter SN; Palù G Curr Med Chem; 2006; 13(11):1305-15. PubMed ID: 16712471 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of intra- and extra-cellular Tat function and HIV expression by pertussis toxin B-oligomer. Rizzi C; Alfano M; Bugatti A; Camozzi M; Poli G; Rusnati M Eur J Immunol; 2004 Feb; 34(2):530-6. PubMed ID: 14768058 [TBL] [Abstract][Full Text] [Related]
36. Small HIV-1-Tat peptides inhibit HIV replication in cultured T-cells. Löhr M; Kibler KV; Zachary I; Jeang KT; Selwood DL Biochem Biophys Res Commun; 2003 Jan; 300(2):609-13. PubMed ID: 12504126 [TBL] [Abstract][Full Text] [Related]
37. A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2'-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA, or 2'-thio-LNA residues. Arzumanov A; Stetsenko DA; Malakhov AD; Reichelt S; Sørensen MD; Babu BR; Wengel J; Gait MJ Oligonucleotides; 2003; 13(6):435-53. PubMed ID: 15025911 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of Tat-mediated transactivation and HIV replication with Tat mutant and repressor domain fusion proteins. Fraisier C; Abraham DA; van Oijen M; Cunliffe V; Irvine A; Craig R; Dzierzak EA Gene Ther; 1998 Jul; 5(7):946-54. PubMed ID: 9813666 [TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological activity of a cyclic peptide: an inhibitor of HIV-1 tat-TAR interactions in human cells. Tamilarasu N; Huq I; Rana TM Bioorg Med Chem Lett; 2000 May; 10(9):971-4. PubMed ID: 10853671 [TBL] [Abstract][Full Text] [Related]
40. Structural elucidation of impurities in 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichlorophenyl)-3H-1,2,4-triazol-3-one (Ib), a novel nonpeptide angiotensin AT1 receptor antagonist. Gao T; Liu Y; Ji Y; Wu X; Xu J J Pharm Biomed Anal; 2012 Jul; 66():381-6. PubMed ID: 22516679 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]